BLOOD 2023: Venetoclax-Based Therapy Effective for Chronic Lymphocytic Leukemia With BTKi Exposure
Time-limited venetoclax-rituximab saw better progression-free survival than monotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.